Insight

Katarzyna Pogoda Shared Study on Paclitaxel Dose Intensity and Outcomes in Early TNBC and HER2-positive Breast Cancer

Katarzyna Pogoda/LinkedIn

Jun 22, 2025, 12:24

Katarzyna Pogoda Shared Study on Paclitaxel Dose Intensity and Outcomes in Early TNBC and HER2-positive Breast Cancer

Katarzyna Pogoda, Medical Oncologist at the Maria Sklodowska-Curie National Research Institute of Oncology, shared a post on LinkedIn:

“Just published!

Association between neoadjuvant paclitaxel dose intensity and outcomes in early TNBC and HER2+ breast cancer: a real-world data analysis.

We’re excited to share the results of our international multicenter study evaluating the impact of paclitaxel dose intensity during neoadjuvant treatment on outcomes in early TNBC and HER2-positive breast cancer.

Key highlights:

77% of patients required paclitaxel dose reductions during neoadjuvant therapy.

In TNBC, dose intensity <69% was associated with significantly lower pCR rates and worse breast cancer-free survival.

Prevention of chemotherapy-induced peripheral neuropathy (CIPN) remains an urgent unmet need.

Further research is warranted, particularly in patients receiving chemo-immunotherapy combinations.

This project was conducted within the framework of Digital Institute for Cancer Outcomes Research – a collaborative European cancer research network using real-world data to accelerate insights into patient outcomes and precision oncology.

Special thanks to Cedric, Eriseld Krasniqi, and Michal for your leadership and unwavering commitment – and to our entire international research team from Belgium, Poland, the United Kingdom, Slovenia, Portugal, France, Italy, and the Czech Republic. This work was only possible thanks to your shared vision and collaboration”

Title: Association between neoadjuvant paclitaxel dose intensity and outcomes in early triple-negative and HER2-positive breast cancer: a real-world data analysis

Journal: ESMO Real World Data and Digital Oncology

Authors: C. van Marcke, K. Pogoda, H. Fenton, M. Vallet, G. Plavc, M. Borges, H. Yousuf, E. Dumas, M. Berliere, G. Ciliberto, F.P. Duhoux, V. Fano, P. Hall, K. Kolenc Mokotar, L. Lopes Conceicao, F. Pereira, A. Škoporc, A. Thomas, G. Tramonti, M.R. van Bockstal, P. Vici, M. Uher, E. Krasniqi

Read the full article.

Paclitaxel Dose

Read more about Paclitaxel in Breast Cancer on OncoDaily.

A Thomas A. Škoporc Breast Cancer C. van Marcke cancer E. Dumas E. Krasniqi ESMO Real World Data and Digital Oncology F. Pereira F.P. Duhoux G. Ciliberto G. Plavc G. Tramonti H. Fenton H. Yousuf HER2 positive breast cancer K. Kolenc Mokotar K. Pogoda Katarzyna Pogoda L. Lopes Conceicao M. Berliere M. Borges M. Uher M. Vallet M.R. van Bockstal Maria Sklodowska-Curie National Research Institute of Oncology OncoDaily Oncology P. Hall P. Vici Paclitaxel TNBC V. Fano

Cancer in Dogs: Common Types, Symptoms, Diagnosis, and Treatment

Cardio-Oncology in Focus: How Chemotherapy Can Harm Heart Health

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?